Schedule 13G ownership disclosure
LUMOS PHARMA INC
Common Stock · CUSIP: 55028X109
Event date: 2024-09-30
- Filing-level shares
- 64,981
- Percent of class
- 0.8%
- Wells Fargo & Company
Shares: 64,981 · Class: 0.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000072971-24-000236
- Form type
- SCHEDULE 13G/A
- Filer
- LUMOS PHARMA, INC.
- CIK
- CIK 1126234
- Filed
- Oct 25, 2024
- Reporting period
- Sep 30, 2024
- Description
- Schedule 13G beneficial ownership